Struggling Orthovita Taps Distributors To Chase Outpatient Vertebroplasties
This article was originally published in The Gray Sheet
Executive Summary
A rapid shift of minimally invasive procedures for vertebrae fractures to the outpatient setting is weighing down Orthovita's growth prospects, but the firm says it plans to leverage external distributors to counteract some of the pressure
You may also be interested in...
Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz
Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.
Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz
Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.
Vertebroplasty Shows No More Benefit Than Sham Procedures In Trials
The first two blinded, randomized, placebo-controlled trials of vertebroplasty treatment for spinal fractures suggest that the procedure may have no lasting benefit, researchers report in the Aug. 6 New England Journal of Medicine